



Supply of Australian labelled Microlut® to New Zealand

27th May 2020

Dear Healthcare Professional,

This communication is intended for Healthcare Professionals (HCPs) primarily involved in the dispensing of Microlut (levonorgestrel) tablets.

Bayer New Zealand Limited
PO BOX 2825
Shortland Street
Auckland 1140
New Zealand

Summary



Bayer is supplying the following batch of the Australian-labelled Microlut to the New Zealand market to cover a medicine shortage which has occurred due to the unprecedented increase in demand during the COVID-19 pandemic and associated lockdown requirements.

www.bayer.co.nz

Batch Number: KT059LF

Expiry Date: 09.2022

Please note that the Microlut tablet formulation and blister platform are identical in the Australian and New Zealand product. However, please note the differences outlined in the table below regarding the carton artwork, pack size, shelf life and storage conditions.

New Zealand labelled Microlut	Australian labelled Microlut
<p>Carton:</p> 	<p>Carton:</p> 
<p>Pack Size: 84 tablets</p>	<p>Pack Size: 112 tablets</p>
<p>Storage: Store at or below 25°C</p>	<p>Storage: Store below 30°C</p>
<p>Shelf Life: 60 months</p>	<p>Shelf Life: 36 months</p>



HCP Information

The prescribing and provision of patient counselling by HCPs should continue in accordance to the New Zealand Data Sheet and Consumer Medicine Information for Microlut. Healthcare Professionals should note that the Patient Information Leaflet in the Australian labelled Microlut presents the precautions and contraindications associated with Microlut in a different manner to the leaflet normally contained in the New Zealand labelled Microlut. **Therefore, please advise patients to access the New Zealand CMI for Microlut available on the Medsafe website.**

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

If you have any questions related to this product please contact our Medical Information department on 0800 229 376.

Yours sincerely,

A blue ink signature of Dr Eduardo Pimenta, appearing as a stylized, cursive 'E' followed by 'Pimenta'.

Dr Eduardo Pimenta
Country Medical Director
Australia & New Zealand

A blue ink signature of Suzanne Subritzky, appearing as a cursive 'suzanne subritzky'.

Suzanne Subritzky
Country Commercial Lead
New Zealand